Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Increases By 513.6%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a large increase in short interest in June. As of June 15th, there was short interest totaling 193,285 shares, an increase of 513.6% from the May 31st total of 31,498 shares. Based on an average daily volume of 12,405,724 shares, the short-interest ratio is currently 0.0 days. Approximately 4.6% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Stock Up 2.0%

Shares of Cyclacel Pharmaceuticals stock opened at $0.61 on Friday. Cyclacel Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $19.87. The firm has a market cap of $3.39 million, a PE ratio of -0.14 and a beta of -0.40. The business’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.10.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.